Propofol ameliorates doxorubicin-induced oxidative stress and cellular apoptosis in rat cardiomyocytes

BackgroundPropofol is an anesthetic with pluripotent cytoprotective properties against various extrinsic insults. This study was designed to examine whether this agent could also ameliorate the infamous toxicity of doxorubicin, a widely-used chemotherapeutic agent against a variety of cancer diseases, on myocardial cells.MethodsCultured neonatal rat cardiomyocytes were administrated with vehicle, doxorubicin (1 μM), propofol (1 μM), or propofol plus doxorubicin (given 1 h post propofol). After 24 h, cells were harvested and specific analyses regarding oxidative/nitrative stress and cellular apoptosis were conducted.ResultsTrypan blue exclusion and MTT assays disclosed that viability of cardiomyocytes was significantly reduced by doxorubicin. Contents of reactive oxygen and nitrogen species were increased and antioxidant enzymes SOD1, SOD2, and GPx were decreased in these doxorubicin-treated cells. Mitochondrial dehydrogenase activity and membrane potential were also depressed, along with activation of key effectors downstream of mitochondrion-dependent apoptotic signaling. Besides, abundance of p53 was elevated and cleavage of PKC-δ was induced in these myocardial cells. In contrast, all of the above oxidative, nitrative and pro-apoptotic events could be suppressed by propofol pretreatment.ConclusionsPropofol could extensively counteract oxidative/nitrative and multiple apoptotic effects of doxorubicin in the heart; hence, this anesthetic may serve as an adjuvant agent to assuage the untoward cardiac effects of doxorubicin in clinical application.

► We evaluate how propofol prevents doxorubicin-induced toxicity in cardiomyocytes. ► Propofol reduces doxorubicin-imposed nitrative and oxidative stress. ► Propofol suppresses mitochondrion-, p53- and PKC-related apoptotic signaling. ► Propofol ameliorates apoptosis and preserves viability of doxorubicin-treated cells. ► Thus, propofol could effectively antagonize doxorubicin toxicity on myocardial cells.